OBJECTIVE: To determine the efficacy of a zoster vaccine on herpes zoster (HR)-related interference with activities of daily living (ADLs) and health-related quality of life (HRQL). DESIGN: Randomized double-blind placebo controlled trial. SETTING: Twenty-two U.S. sites. PARTICIPANTS: Thirty eight thousand five hundredforty-six women and men aged 60 and olcer. MEASUREMENTS: HZ burden of interference with ADLs and HRQL using ratings from the Zoster Brief Pain Inventory (ZBPI) and Medical Outcomes Study 12-item Short Form Survey (SF-12) mental component summary (MCS) and physical component summary (PCS) scores. Vaccine efficacy was calculated for the modified-intention-to-treat trial population and solely in participants who developed HZ. RESULTS: For the modified-intention-to-treat population, the overall zoster vaccine efficacy was 66% (95% confidence interval (CI)=55-74%) for ZBPI ADL burden of interference score and 55% (95% CI=48-61%) for both the SF-12 MCS and PCS scores. Of participants who developed HZ, zoster vaccine reduced the ZBPI ADL burden of interference score by 31% (95% CI=12-51%) and did not significantly reduce the effect on HRQL. CONCLUSIONS:Zoster vaccine reduced the burden of HZ-related interference with ADLs in the population of vaccinees and in vaccinees who developed HZ. Zoster vaccine reduced the effect of HZ on HRQL in the population of vaccinees but not in vaccinees who developed HZ.
RCT Entities:
OBJECTIVE: To determine the efficacy of a zoster vaccine on herpes zoster (HR)-related interference with activities of daily living (ADLs) and health-related quality of life (HRQL). DESIGN: Randomized double-blind placebo controlled trial. SETTING: Twenty-two U.S. sites. PARTICIPANTS: Thirty eight thousand five hundred forty-six women and men aged 60 and olcer. MEASUREMENTS: HZ burden of interference with ADLs and HRQL using ratings from the Zoster Brief Pain Inventory (ZBPI) and Medical Outcomes Study 12-item Short Form Survey (SF-12) mental component summary (MCS) and physical component summary (PCS) scores. Vaccine efficacy was calculated for the modified-intention-to-treat trial population and solely in participants who developed HZ. RESULTS: For the modified-intention-to-treat population, the overall zoster vaccine efficacy was 66% (95% confidence interval (CI)=55-74%) for ZBPI ADL burden of interference score and 55% (95% CI=48-61%) for both the SF-12MCS and PCS scores. Of participants who developed HZ, zoster vaccine reduced the ZBPI ADL burden of interference score by 31% (95% CI=12-51%) and did not significantly reduce the effect on HRQL. CONCLUSIONS: Zoster vaccine reduced the burden of HZ-related interference with ADLs in the population of vaccinees and in vaccinees who developed HZ. Zoster vaccine reduced the effect of HZ on HRQL in the population of vaccinees but not in vaccinees who developed HZ.
Authors: Jennifer Katz; Edith M Cooper; Robert R Walther; Eugene W Sweeney; Robert H Dworkin Journal: Clin Infect Dis Date: 2004-07-19 Impact factor: 9.079
Authors: M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber Journal: N Engl J Med Date: 2005-06-02 Impact factor: 91.245
Authors: C Chidiac; J Bruxelle; J P Daures; T Hoang-Xuan; P Morel; A Leplège; A El Hasnaoui; C de Labareyre Journal: Clin Infect Dis Date: 2001-06-05 Impact factor: 9.079
Authors: Kenneth E Schmader; Richard Sloane; Carl Pieper; Paul M Coplan; Alexander Nikas; Patricia Saddier; Ivan S F Chan; Peter Choo; Myron J Levin; Gary Johnson; Heather M Williams; Michael N Oxman Journal: Clin J Pain Date: 2007 Jul-Aug Impact factor: 3.442
Authors: Paul M Coplan; Kenneth Schmader; Alexander Nikas; Ivan S F Chan; Peter Choo; Myron J Levin; Gary Johnson; Mark Bauer; Heather M Williams; Karen M Kaplan; Harry A Guess; Michael N Oxman Journal: J Pain Date: 2004-08 Impact factor: 5.820
Authors: Kenneth E Schmader; Myron J Levin; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino Journal: Clin Infect Dis Date: 2012-01-30 Impact factor: 9.079
Authors: Jean-Marc G Guedon; Michael B Yee; Mingdi Zhang; Stephen A K Harvey; William F Goins; Paul R Kinchington Journal: Virology Date: 2015-04-11 Impact factor: 3.616
Authors: Anne A Gershon; Judith Breuer; Jeffrey I Cohen; Randall J Cohrs; Michael D Gershon; Don Gilden; Charles Grose; Sophie Hambleton; Peter G E Kennedy; Michael N Oxman; Jane F Seward; Koichi Yamanishi Journal: Nat Rev Dis Primers Date: 2015-07-02 Impact factor: 52.329